Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J Clinicians. 2021;71(3):209–49.

Google Scholar 

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.

Article  PubMed  CAS  Google Scholar 

Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212–24.

Article  PubMed  CAS  Google Scholar 

Yuan S-Q, Nie R-C, Jin Y, Liang C-C, Li Y-F, Jian R, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30(2):552–9.

Article  PubMed  CAS  Google Scholar 

André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clinical Oncol : Official J the Am Soc Clinical Oncol. 2023;41(2):255–65.

Article  Google Scholar 

Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, et al. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer : Official J the Int Gastric Cancer Association Japanese Gastric Cancer Association. 2022;25(3):619–28.

Article  CAS  Google Scholar 

Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10+GPR77+ Cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841-856.e16.

Article  PubMed  CAS  Google Scholar 

Gao Y, Li X, Zeng C, Liu C, Hao Q, Li W, et al. CD63+ Cancer-Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR-22. Adv Sci. 2020;7(21):2002518.

Article  CAS  Google Scholar 

Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70.

Article  PubMed  PubMed Central  Google Scholar 

Chhabra Y, Weeraratna AT. Fibroblasts in cancer: Unity in heterogeneity. Cell. 2023;186(8):1580–609.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.

Article  PubMed  PubMed Central  Google Scholar 

Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102–23.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zheng H, An M, Luo Y, Diao X, Zhong W, Pang M, et al. PDGFRα+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. Cancer Cell. 2024;42(4):682-700.e12.

Article  PubMed  CAS  Google Scholar 

Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, et al. TSPAN8+ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024;16(741):eadj5705.

Article  PubMed  CAS  Google Scholar 

Pan W, Cheng Y, Zhang H, Liu B, Mo X, Li T, et al. CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest. Sci Rep. 2014;4:6812.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao B, Gong W, Ma A, Chen J, Velegraki M, Dong H, et al. SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. Nat Immunol. 2022;23(11):1588–99.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sheets JN, Iwanicki M, Liu JF, Howitt BE, Hirsch MS, Gubbels JAA, et al. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis. 2016;5(10): e264.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guo W, Shao F, Sun S, Song P, Guo L, Xue X, et al. Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. J Cancer. 2020;11(7):1648–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sheets JN, Patrick ME, Egland KA. SUSD2 expression correlates with decreased metastasis and increased survival in a high-grade serous ovarian cancer xenograft murine model. Oncotarget. 2020;11(24):2290–301.

Article  PubMed  PubMed Central  Google Scholar 

Xu Y, Miao C, Jin C, Qiu C, Li Y, Sun X, et al. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer. Exp Cell Res. 2018;363(2):160–70.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London, England). 2021;398(10294):27–40.

Article  PubMed  CAS  Google Scholar 

Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017;3(12): e173290.

Article  PubMed  PubMed Central  Google Scholar 

Pan Y, Lu F, Fei Q, Yu X, Xiong P, Yu X, et al. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. J Hematol Oncol. 2019;12(1):124.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical Cancer Res : an Official J the Am Association For Cancer Res. 2008;14(16):5220–7.

Article  CAS  Google Scholar 

Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resistance Updates : Rev Commentaries In Antimicrobial Anticancer Chemother. 2023;68: 100960.

Article  CAS  Google Scholar 

Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, et al. Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer Sci. 2018;109(5):1480–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Patrick ME, Egland KA. SUSD2 Proteolytic Cleavage Requires the GDPH Sequence and Inter-Fragment Disulfide Bonds for Surface Presentation of Galectin-1 on Breast Cancer Cells. Int J Mol Sci. 2019;20(15):3814.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57(2):206–22.

Article  PubMed  CAS  Google Scholar 

Li R, Liu H, Cao Y, Wang J, Chen Y, Qi Y, et al. Identification and validation of an immunogenic su